CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis
8 affiliations
- 1DePaul University , , ,
- 2Narendra Modi Medical College , ,
- 3Rashid Latif Medical College , ,
- 4Fanarjyan Clinic , ,
- 5Kathmandu University School of Medical Sciences , ,
- 6Services Institute of Medical Sciences , ,
- 7American University of Antigua , ,
- 8King Edward Medical University , ,
Abstract
Introduction: Semaglutide 2.4 mg is the reference pharmacotherapy for weight management, yet many patients do not reach ambitious weight-loss targets. CagriSema, a fixed-dose combination of cagrilintide and semaglutide, may offer additional benefit through complementary mechanisms. We quantified its incremental efficacy and safety against semaglutide 2.4 mg monotherapy in adults with overweight or obesity, with and without type 2 diabetes.
Methods: This PRISMA 2020–compliant review (PROSPERO CRD420261380458) searched PubMed, Embase, Cochrane CENTRAL, ScienceDirect, ClinicalTrials.gov and WHO ICTRP to 30 June 2026 for randomised controlled trials comparing CagriSema with semaglutide 2.4 mg or placebo. Effects were pooled within two prespecified comparator strata using random-effects models with restricted maximum likelihood estimation of τ² and a Hartung–Knapp–Sidik–Jonkman small-sample adjustment, with prediction intervals, leave-one-out and phase-3a-restricted sensitivity analyses, trial sequential analysis.
Results: Five trials (4,746 unique participants) were included. Versus semaglutide 2.4 mg, CagriSema produced greater weight loss (mean difference −6.89 percentage points, 95% CI −8.70 to −5.06; I² = 33%; prediction interval −8.91 to −4.86), a greater absolute reduction in body weight (−7.16 kg, 95% CI −9.15 to −5.17) and in body-mass index (−2.41 kg/m², 95% CI −2.83 to −1.99), and roughly twice the likelihood of reaching a 20% reduction (RR 2.10, 95% CI 1.78 to 2.47). Waist circumference fell further (−4.07 cm, 95% CI −5.10 to −3.04). No incremental glycaemic benefit was detected, with intervals for glycated haemoglobin (−0.07, 95% CI −0.14 to 0.01) and fasting plasma glucose lying entirely within prespecified minimal important differences. Injection-site reactions were more frequent (RR 3.14, 95% CI 1.42 to 6.96); gastrointestinal adverse events were not significantly increased under the primary model (RR 1.09, 95% CI 0.97 to 1.21).
Conclusion: CagriSema produces clinically meaningful additional weight loss and modest improvements in surrogate cardiometabolic measures compared with semaglutide 2.4 mg alone, at the cost of more frequent injection-site reactions and, at most, modestly more frequent gastrointestinal events. The evidence is insufficient to determine whether serious adverse events or neoplasms differ between treatments, and long-term durability, cardiovascular outcomes and body composition remain undetermined.
Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420261380458.
Related
- Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials
- Advances in pharmacologic management of obesity: oral semaglutide for weight management
- Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study
- Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study
- Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review
BibTeX
@article{rasool2026cagrisema,
title = {{CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis}},
author = {Zehra Khatoon Rasool and Rajvi Shah and Ansharah E Zinnia Batool and Rutvi Shah and Mariam Khachatryan and Sushant Bhardwaj and Ahmad Ali and Meeran Atta and Pugazhandhi Bakthavatchalam and Mirza Muhammad Hadeed Khawar and Muneeb Khawar},
journal = {Frontiers in endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1903335},
url = {https://europepmc.org/article/PMC/PMC13673521},
note = {CC BY},
}
RIS
TY - JOUR
TI - CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis
AU - Zehra Khatoon Rasool
AU - Rajvi Shah
AU - Ansharah E Zinnia Batool
AU - Rutvi Shah
AU - Mariam Khachatryan
AU - Sushant Bhardwaj
AU - Ahmad Ali
AU - Meeran Atta
AU - Pugazhandhi Bakthavatchalam
AU - Mirza Muhammad Hadeed Khawar
AU - Muneeb Khawar
PY - 2026
DA - 2026/10/02
JO - Frontiers in endocrinology
DO - 10.3389/fendo.2026.1903335
UR - https://europepmc.org/article/PMC/PMC13673521
AB - Introduction: Semaglutide 2.4 mg is the reference pharmacotherapy for weight management, yet many patients do not reach ambitious weight-loss targets. CagriSema, a fixed-dose combination of cagrilintide and semaglutide, may offer additional benefit through complementary mechanisms. We quantified its incremental efficacy and safety against semaglutide 2.4 mg monotherapy in adults with overweight or obesity, with and without type 2 diabetes. Methods: This PRISMA 2020–compliant review (PROSPERO CRD420261380458) searched PubMed, Embase, Cochrane CENTRAL, ScienceDirect, ClinicalTrials.gov and WHO ICTRP to 30 June 2026 for randomised controlled trials comparing CagriSema with semaglutide 2.4 mg or placebo. Effects were pooled within two prespecified comparator strata using random-effects models with restricted maximum likelihood estimation of τ² and a Hartung–Knapp–Sidik–Jonkman small-sample adjustment, with prediction intervals, leave-one-out and phase-3a-restricted sensitivity analyses, trial sequential analysis. Results: Five trials (4,746 unique participants) were included. Versus semaglutide 2.4 mg, CagriSema produced greater weight loss (mean difference −6.89 percentage points, 95% CI −8.70 to −5.06; I² = 33%; prediction interval −8.91 to −4.86), a greater absolute reduction in body weight (−7.16 kg, 95% CI −9.15 to −5.17) and in body-mass index (−2.41 kg/m², 95% CI −2.83 to −1.99), and roughly twice the likelihood of reaching a 20% reduction (RR 2.10, 95% CI 1.78 to 2.47). Waist circumference fell further (−4.07 cm, 95% CI −5.10 to −3.04). No incremental glycaemic benefit was detected, with intervals for glycated haemoglobin (−0.07, 95% CI −0.14 to 0.01) and fasting plasma glucose lying entirely within prespecified minimal important differences. Injection-site reactions were more frequent (RR 3.14, 95% CI 1.42 to 6.96); gastrointestinal adverse events were not significantly increased under the primary model (RR 1.09, 95% CI 0.97 to 1.21). Conclusion: CagriSema produces clinically meaningful additional weight loss and modest improvements in surrogate cardiometabolic measures compared with semaglutide 2.4 mg alone, at the cost of more frequent injection-site reactions and, at most, modestly more frequent gastrointestinal events. The evidence is insufficient to determine whether serious adverse events or neoplasms differ between treatments, and long-term durability, cardiovascular outcomes and body composition remain undetermined. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420261380458.
SN - 1664-2392
ER -